Evidence map›Paper›PMID 30072596›Full record

ArticleInternational journal of molecular sciences2018

IL-37 Expression Reduces Lean Body Mass in Mice by Reducing Food Intake.

Eline N Kuipers, Andrea D van Dam, Dov B Ballak, Ellemiek A de Wit, Charles A Dinarello, Rinke Stienstra, Janna A van Diepen, Patrick C N Rensen, Mariëtte R Boon

Open access · goldAbstract read
In one paragraph

Article in International journal of molecular sciences, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.3field-weighted citation impact, top 44% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Review
  3. IL-37-a putative therapeutic agent in cardiovascular diseases.QJM : monthly journal of the Association of Physicians · 2022
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 2 countries.

Eline N KuipersDepartment of Medicine, Division of Endocrinology, Leiden University Medical Center, Post Zone C7Q, P.O. Box 9600, 2300 RC Leiden, The Netherlands. e.n.kuipers@lumc.nl.ORCID 0000-0003-1360-7525
Andrea D van DamDepartment of Medicine, Division of Endocrinology, Leiden University Medical Center, Post Zone C7Q, P.O. Box 9600, 2300 RC Leiden, The Netherlands. a.d.van_dam@lumc.nl.
Dov B BallakDepartment of Medicine, University of Colorado, Aurora, CO 80045, USA. dov.ballak@Radboudumc.nl.ORCID 0000-0002-1530-9743
Ellemiek A de WitDepartment of Medicine, Division of Endocrinology, Leiden University Medical Center, Post Zone C7Q, P.O. Box 9600, 2300 RC Leiden, The Netherlands. ellemiekdewit@gmail.com.
Charles A DinarelloDepartment of Medicine, University of Colorado, Aurora, CO 80045, USA. cdinare333@aol.com.
Rinke StienstraDepartment of General Internal Medicine and Radboud Center for Infectious Diseases, Radboud University Nijmegen Medical Center, 6525 HP Nijmegen, The Netherlands. rinke.stienstra@radboudumc.nl.
Janna A van DiepenDepartment of General Internal Medicine and Radboud Center for Infectious Diseases, Radboud University Nijmegen Medical Center, 6525 HP Nijmegen, The Netherlands. janna.vandiepen@radboudumc.nl.ORCID 0000-0001-9091-1075
Patrick C N RensenDepartment of Medicine, Division of Endocrinology, Leiden University Medical Center, Post Zone C7Q, P.O. Box 9600, 2300 RC Leiden, The Netherlands. p.c.n.rensen@lumc.nl.ORCID 0000-0002-8455-4988
Mariëtte R BoonDepartment of Medicine, Division of Endocrinology, Leiden University Medical Center, Post Zone C7Q, P.O. Box 9600, 2300 RC Leiden, The Netherlands. m.r.boon@lumc.nl.
Leiden University Medical Center · NLRadboud University Nijmegen · NLUniversity of Colorado Anschutz Medical Campus · US

Funding

Yeast-based HTS Assay Technologies for ProteasesR01AI015614 · NIAID · UNIVERSITY OF COLORADO DENVER · PI DINARELLO, CHARLES ANTHONY · 1985 to 2025
$8.5M
NIAID NIH HHS R01 AI015614
6 · The paper itself

Abstract

The human cytokine interleukin (IL)-37 is an anti-inflammatory member of the IL-1 family of cytokines. Transgenic expression of IL-37 in mice protects them from diet-induced obesity and associated metabolic complications including dyslipidemia, inflammation and insulin resistance. The precise mechanism of action leading to these beneficial metabolic effects is not entirely known. Therefore, we aimed to assess in detail the effect of transgenic IL-37 expression on energy balance, including food intake and energy expenditure. Feeding homozygous IL-37 transgenic mice and wild-type (WT) control mice a high-fat diet (HFD; 45% kcal palm fat) for 6 weeks showed that IL-37 reduced body weight related to a marked decrease in food intake. Subsequent mechanistic studies in mice with heterozygous IL-37 expression versus WT littermates, fed the HFD for 18 weeks, confirmed that IL-37 reduces food intake, which led to a decrease in lean body mass, but did not reduce fat mass and plasma lipid levels or alterations in energy expenditure independent of lean body mass. Taken together, this suggests that IL-37 reduces lean body mass by reducing food intake.

Indexed as

Body WeightEatingUp-RegulationAnimalsBlood GlucoseBody CompositionDiet, High-FatEnergy MetabolismHumansInterleukin-1LipidsMaleMice, Inbred C57BLMice, TransgenicObesityBlood GlucoseIL37 protein, humanInterleukin-1Lipidsenergy metabolismfood intakehigh fat dietIL-37

Identifiers

PMID30072596
PMCPMC6121375
OpenAlexW2885799115

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.